Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
4.260
-0.180 (-4.05%)
At close: Dec 19, 2025, 4:00 PM EST
4.390
+0.130 (3.05%)
After-hours: Dec 19, 2025, 7:59 PM EST
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 800 employees as of December 31, 2024. The number of employees increased by 300 or 60.00% compared to the previous year.
Employees
800
Change (1Y)
300
Growth (1Y)
60.00%
Revenue / Employee
$54,611
Profits / Employee
-$894,429
Market Cap
2.22B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 800 | 300 | 60.00% |
| Dec 31, 2023 | 500 | 0 | - |
| Dec 31, 2022 | 500 | 100 | 25.00% |
| Dec 31, 2021 | 400 | 69 | 20.85% |
| Dec 31, 2020 | 331 | 131 | 65.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RXRX News
- 3 days ago - Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 - Seeking Alpha
- 3 days ago - What's Happening With RXRX Stock? - Forbes
- 13 days ago - Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript - Seeking Alpha
- 13 days ago - Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial - Reuters
- 13 days ago - Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks - GlobeNewsWire
- 16 days ago - Jim Cramer: This Health Care Stock Has Been 'Horrendous' - Benzinga
- 20 days ago - Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 - GlobeNewsWire
- 4 weeks ago - Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha